Table 1 Clinical, hematologic, and cytogenetic characteristics of the MDS patients

From: Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

 

Age

Sex

Diagnosis

Screening

Karyotype [no. metaphases with aberration]

Clinical outcome

Total cycles

Duration of therapy (months)

Time to first response (cycles)

Duration of response (months)

Survival (months)

Time to AML Evolution (months)

Cause of death

WHO

WPSS

a1

67

M

RAEB-2

VERY- HIGH

25/03/2013

COMPLEX

SD

10

10

NA

NA

14

8

AML

a2

67

F

RAEB-2

HIGH

02/04/2013

46, XX

CR

30

28

6

24

35

28

OVARIAN CANCER

a3

71

M

RAEB-2

HIGH

29/04/2013

47, XY, +8 [8]

mCR

38

36

4

10

41

36

AML, INFECTION

a4

76

F

RAEB-2

HIGH

13/05/2013

46, XX [1]

HI

8

8

4

3

12

9

AML, CACHEXIA

a5

68

M

RAEB-1

HIGH

13/05/2013

COMPLEX

SD

9

9

NA

NA

14

 

PNEUMONIA, CARDIAC FAILURE

a6

67

M

RAEB-2

HIGH

23/05/2013

46, XY

PR

10

10

2

5

30

10

AML

a7

72

M

RAEB-1

HIGH

26/06/2013

46, XY, del(7)(q22;34) [20]; del(7q31) [18]

SD

8

8

NA

NA

22

20

CEREBRAL HEMORRHAGE

8

82

M

RAEB-2

HIGH

28/06/2013

46, XY

CR

41

42

2

40

42

  

9

67

F

RAEB-1

HIGH

01/07/2013

47, XX, +8

HI + mCR

12

18

2 (mCR); 5 (HI)

8 (HI); 16 (mCR)

42

  

10

73

F

RAEB-1

INT

10/07/2013

45, X, del(X), del(20q)

HI + mCR

38

42

3 (HI) + 4 (mCR)

35 (HI); 34 (mCR)

42

  

a11

75

F

RAEB-1

HIGH

10/07/2013

47, XX, +8

HI

20

21

1

19

28

21

DISEASE PROGRESSION

12

76

M

RAEB-1

INT

22/07/2013

46, XY

HI + mCR

8

8

1

5 (HI); 6 (mCR)

38

  

a13

74

M

RAEB-2

ND

24/07/2013

ND

NA

1

1

NA

NA

2

 

PNEUMONIA

a14

78

M

RAEB-2

HIGH

05/08/2013

46, XY

HI

19

25

8

9

27

25

AML

a15

72

M

RAEB-2

HIGH

28/08/2013

46, XY, del(5), del(9)

NA

2

3

NA

NA

12

 

WORSENING OF CLINICAL CONDITIONS

16

70

M

RAEB-2

HIGH

29/08/2013

46, XY

CR

27

40

2

38

40

  

a17

75

F

RAEB-2

HIGH

03/09/2013

46, XX, t(2;15)(q23;q26)

DP

2

2

NA

NA

5

2

AML

a18

72

F

RCMD- RS

HIGH

09/09/2013

COMPLEX

HI + mCR

13

14

2

11

16

15

AML, SEPSIS

a19

62

M

RAEB-1

HIGH

17/09/2013

46, XY, del(7), +X, [18]

CR

6

7

1

5

14

 

CARDIAC EVENT

a20

70

F

RAEB-2

HIGH

23/09/2013

46, XX

NA

2

2

NA

NA

2

 

COPD

a21

82

M

RCMD

HIGH

23/09/2013

47, XY, +8, −9,+3mar

HI

20

28

6

18

28

 

RESPIRATORY FAILURE

22

82

M

RAEB-2

HIGH

25/09/2013

46, XY, del(20q)

CR

36

39

1

38

39

  

a23

68

M

RCMD

HIGH

03/10/2013

45, XY, del(7)

HI

3

3

1

2

3

 

SUDDEN DEATH

24

75

M

RAEB-2

VERY- HIGH

28/10/2013

45, XY, del(7), del(20)(q11)[3] / 46, XY [17]

NA

1

1

NA

NA

35

  

a25

66

F

RAEB-2

HIGH

15/10/2013

46, XX

SD

8

8

NA

NA

14

14

AML

a26

77

M

RAEB-2

HIGH

30/10/2013

46, XXYY [5]

NA

1

1

NA

NA

5

 

HEART FAILURE

a27

48

F

RAEB-2

VERY- HIGH

06/11/2013

47, XY, + 8

CR

16

15

2

11

26

 

DISEASE PROGRESSION

a28

64

F

RAEB-1

INT

06/11/2013

46, XX

HI

10

10

5

3

12

 

PULMONARY CARCINOMA

a29

79

F

RAEB-2

ND

13/11/2013

ND

NA

2

2

NA

NA

3

 

HEART ATTACK

a30

66

M

RAEB-2

VERY- HIGH

15/11/2013

47, XY, +8

HI

9

9

3

4

10

 

WORSENING OF CLINICAL CONDITIONS

a31

75

F

RAEB-2

HIGH

22/11/2013

46, XX

HI

10

10

2

5

11

11

AML

a32

83

M

RAEB-2

HIGH

04/02/2014

47, XX, +8 [5]

SD

6

6

NA

NA

11

9

AML

a33

71

F

RAEB-2

VERY- HIGH

17/02/2014

COMPLEX

CR

7

7

2

5

12

9

AML, SEPSIS

a34

66

F

RAEB-2

VERY- HIGH

10/03/2014

COMPLEX

DP

1

1

NA

NA

2

1

AML, INFECTION

35

72

M

RAEB-1

VERY- HIGH

14/04/2014

COMPLEX

HI + mCR

11

11

4 (HI + mCR)

6 (HI)

32

  

a36

69

M

RAEB-2

HIGH

19/05/2014

46, XY

mCR

6

6

2

3

16

13

AML

37

70

M

RAEB-1

HIGH

19/05/2014

46, XY, del(7q31)

SD

7

9

NA

NA

31

  

a38

77

F

RAEB-2

VERY- HIGH

19/05/2014

COMPLEX

NA

2

4

NA

NA

4

 

BILATERAL PNEUMONIA

a39

82

F

RAEB-1

VERY- HIGH

04/08/2014

COMPLEX

NA

1

2

NA

NA

7

3

AML

a40

80

M

RAEB-2

VERY- HIGH

15/09/2014

46, XY, t(9,17) (p36;q23) [19]

NA

2

2

NA

NA

2

 

CACHEXIA, HEPATIC FAILURE

a41

78

M

RAEB-2

HIGH

19/08/2014

46, XY

HI + mCR

17

16

2 (HI); 2 (mCR)

14 (HI); 14 (mCR)

17

 

UNKNOWN

42

74

M

RAEB-2

VERY- HIGH

18/08/2014

46, XY, del(7) [1]

CR

26

28

1

27

28

  

a43

66

M

RAEB-2

HIGH

20/10/2014

46, XY

NA

2

2

NA

NA

7

 

RESPIRATORY FAILURE

44

76

M

RAEB-2

HIGH

09/12/2014

46, XY

mCR

22

25

4

21

25

  
  1. WHO World Health Organization; WPSS WHO Prognostic Scoring System; RAEB refractory anemia with excess of blasts; RCMD refractory cytopenia with multilineage dysplasia; RCMD-RS refractory cytopenia with multilineage dysplasia and ringed sideroblasts; VERY-HIGH very-high-risk; HIGH high-risk; INT intermediate risk; CR complete remission; mCR marrow complete remission; PR partial remission; HI hematologic improvement; SD stable disease; DP disease progression; AML acute myeloid leukemia; COPD chronic obstructive pulmonary disease
  2. aPatients deceased during follow-up